EquityBulls

Latest News

APSEZ handles 16% YoY higher cargo volume in Aug'25
Syrma SGS and Elemaster announce strategic JV to strengthen High-Reliability Electronics Manufacturing in India
Fortis Healthcare Expands NCR Presence; Takes Over 200-Bed Greater Noida Hospital on long term lease
Kesar Petroproducts Ltd receives CTO from MPCB for its 1.5 MW Co-Gen power plant
Medanta expands in Delhi-NCR with launch of 550-Bed Super Specialty Hospital in Noida

Keywords Selected: INE044A01036

Stock Report

Sun Pharmaceutical Industries Ltd group has signed settlement agreement in the In re Generic Pharmaceuticals Pricing Antitrust Litigation
Sun Pharma's Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg in Active Psoriatic Arthritis Meet their Primary Endpoint
Philogen provides update on Marketing Authorization application for Nidlegy™ in the European Union
Sun Pharma appoints Kirti Ganorkar as the MD, Dilip Shanghvi to continue as the Executive Chairman of the Board
Sun Pharma gets 8 observations from USFDA for Halol facility
Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis
Order Vacating Preliminary Injunction on LEQSELVI™
Sun Pharma introduces a novel class of drug, Fexuclue® in India for treatment of Erosive Esophagitis
Sun Pharma to acquire Checkpoint Therapeutics
Sun Pharma Presents New Clinical Efficacy and Safety Data in Severe Dermatological Conditions at the 2024 EADV Congress
Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain
Sun Pharma introduces a novel treatment, STARIZO in India for acute bacterial skin and skin structure infections
Submission of Nidlegy™ Marketing Authorization Application Validated by EMA
Sun Pharma Completes Taro Merger
Sun Pharmaceutical Industries Ltd receives warning letter from USFDA for Dadra facility
Sun Pharma and Moebius Medical Ltd present Phase 2b study on MM-II
Sun Pharma to acquire stake in HaystackAnalytics Pvt Ltd
Nidlegy™ Marketing Authorization Application Submitted to EMA
Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024
Taro Shareholders Approve Merger with Sun Pharma
Sun Pharma's Dadra facility receives OAI status from US FDA
Sun Pharmaceuticals announces approval of Winlevi® in Australia
Sun Pharma included in S&P Global Sustainability Yearbook 2024
Taro announces merger agreement with Sun Pharma